First-in-man study of tafluposide, a novel inhibitor of topoisomerase I and II

被引：0
|
作者：
Delord, Jean-Pierre [1 ]
Bennouna, Jaafar [2 ]
Dieras, Veronique [3 ]
Campone, Mario [2 ]
Lefresne, Florence [4 ]
Aslanis, Vassili [5 ]
Douillard, Jean-Yves [2 ]
机构：
[1] Inst Claudius Regaud, Toulouse, France
[2] Ctr Rene Gauducheau, F-44035 Nantes, France
[3] Inst Curie, Paris, France
[4] Inst Rech Pierre Fabre, Boulogne, France
[5] Inst Rech Pierre Fabre, Castres, France
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3380S / 3380S
页数：1
相关论文
共 50 条
  • [41] Lamellarin D:: A novel potent inhibitor of topoisomerase I
    Facompré, M
    Tardy, C
    Bal-Mahieu, C
    Colson, P
    Perez, C
    Manzanares, I
    Cuevas, C
    Bailly, C
    CANCER RESEARCH, 2003, 63 (21) : 7392 - 7399
  • [42] FIRST-IN-MAN STUDY OF LOW-DOSE PACLITAXEL -ELUTING STENT WITH A NOVEL BIODEGRADABLE COATING
    Nakatani, Daisaku
    Honda, Yasuhiro
    Waseda, Katsuhisa
    Ako, Junya
    Calderas, Carlos
    Condado, Jose A.
    Fitzgerald, Peter J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [43] Synthetic approach to hypoxyxylerone, novel inhibitor of topoisomerase I
    Piettre, A
    Chevenier, E
    Massardier, C
    Gimbert, Y
    Greene, AE
    ORGANIC LETTERS, 2002, 4 (18) : 3139 - 3142
  • [44] Mechanism of hydrolysis of a novel indolocarbazole topoisomerase I inhibitor
    Breslin, David
    Sato, Yuichi
    Karki, Shyam B.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 39 (05) : 291 - 297
  • [45] Isodiospyrin as a novel human DNA topoisomerase I inhibitor
    Ting, CY
    Hsu, CT
    Hsu, HT
    Su, JS
    Chen, TY
    Tarn, WY
    Kuo, YH
    Whang-Peng, J
    Liu, LF
    Hwang, JL
    BIOCHEMICAL PHARMACOLOGY, 2003, 66 (10) : 1981 - 1991
  • [46] First-in-man feasibility study of a novel ingestible magnetically inflated balloon capsule for treatment of obesity
    Kaan, Hung Leng
    Phan, Phuoc Thien
    Tiong, Anthony Meng Huat
    Miyasaka, Muneaki
    Phee, Soo Jay
    Ho, Khek Yu
    ENDOSCOPY INTERNATIONAL OPEN, 2020, 8 (05) : E607 - E610
  • [47] Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
    Ando, M
    Eguchi, K
    Shinkai, T
    Tamura, T
    Ohe, Y
    Yamamoto, N
    Kurata, T
    Kasai, T
    Ohmatsu, H
    Kubota, K
    Sekine, I
    Hojo, N
    Matsumoto, T
    Kodama, T
    Kakinuma, R
    Nishiwaki, Y
    Saijo, N
    BRITISH JOURNAL OF CANCER, 1997, 76 (11) : 1494 - 1499
  • [48] First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies
    Ang, J. E.
    Hauns, B.
    Mais, A.
    Parker, A.
    Lal, R.
    Olmos, D.
    Mollenhauer, M.
    Walz, A.
    de Bono, J. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 123 - 124
  • [49] Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
    M Ando
    K Eguchi
    T Shinkai
    T Tamura
    Y Ohe
    N Yamamoto
    T Kurata
    T Kasai
    H Ohmatsu
    K Kubota
    I Sekine
    N Hojo
    T Matsumoto
    T Kodama
    R Kakinuma
    Y Nishiwaki
    N Saijo
    British Journal of Cancer, 1997, 76 : 1494 - 1499
  • [50] Near-thorough QT study as part of a first-in-man study
    Malik, Marek
    Hnatkova, Katerina
    Ford, John
    Madge, David
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (10): : 1146 - 1157
12345